Angiotensin II receptor blockers in arterial hypertension: when to start?


Cite item

Full Text

Abstract

Reasons for start of antihypertensive therapy from angiotensin II receptor blockers are discussed.

About the authors

- -

References

  1. Российское Медицинское Общество по Артериальной Гипертонии - Всероссийское Научное Общество Кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008
  2. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 2005; 45(5): 712-719
  3. Healey J.S., Baranchuk A., Crystal E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 2005; 45(11): 1832-1839
  4. Okazaki Н., Minamino T, Tsukamoto O. et al. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens. Res. 2006; 29(4): 277-284
  5. Dagres N., Karatasakis G., Panou F. et al. Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur. Heart J. 2006; 27(17): 2062-2068
  6. Madrid A.H., Bueno M.G., Rebollo J.M.G. et al. Use of irbesartan to maitain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336
  7. The Active Steering Committee; ACTIVE Investigators, Connolly S., Yusuf S., Budaj A. et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am. Heart J. 2006; 151(6): 1187-1193
  8. Watanabe H., Watanabe T., Sasaki S. et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am.Heart J. 2009; 158(4): 629-636
  9. McManus D.D., Corteville D.C., Shlipak M.G. et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am. J. Cardiol. 2009; 104(11): 1551-1555
  10. Iguchi Y., Kimura K., Kobayashi K. et al. Relation of atrial fibrillation to glomerular filtration rate. Am. J. Cardiol. 2008; 102(8): 1056-1059
  11. Parving H-H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870 - 878
  12. Opie L.H., Parving H.-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643 - 645
  13. Bramlage P., Pittrow D., Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr. Med. Res. Opin. 2004; 20(10): 1625-1631
  14. Rodby R.A., Rohde R.D., Clarke W.R. et al. The irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol. Dial. Transplant. 2000; 15: 487 - 97
  15. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851 - 60
  16. Berl T., Hunsicker L.G., Lewis J.B. et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann. Intern. Med. 2003; 138(7): 542-549
  17. Pohl M.A., Blumenthal S., Cordonnier D.J. et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J. Am. Soc. Nephrol. 2005; 16(10): 3027-3037
  18. Berl T., Hunsicker L.G., Lewis J.B. et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 2005; 16(7): 2170-2179
  19. Anavekar N.S., Gans D.J., Berl T. et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. 2004; (92): S50-S55
  20. Atkins R.C., Briganti E.M., Lewis J.B. et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am. J. Kidney Dis. 2005; 45(2): 281-287
  21. Schupp M., Pharm B., Janke J. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-γ activity. Circulation 2004; 109: 2054 - 2057
  22. Ernsberger P., Koletsky R.J. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr. Opin. Pharmacol. 2007; 7(2): 140-145
  23. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сonsilium Medicum 2006; 8(11): 25 - 30
  24. Kintscher U., Bramlage P., Paar W.D. et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 2007; 6: 12
  25. Sharma A.M. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004; 44: 12 - 19
  26. Shankar S.S., Steinberg H.O. Obesity and endothelial dysfunction. Semin. Vasc. Med. 2005; 5: 56 - 64
  27. Di Filippo C., Lampa E., Tufariello E. et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes. Res. 2005; 13(11): 1909-1914
  28. Voigt J.P., Bramlage P., Fink H. Hypophagic effect of the angiotensin AT(1) receptor antagonist irbesartan in rats. Eur. J. Pharmacol. 2007; 535: 233 - 237
  29. Clasen R., Schupp M., Foryst-Ludwig A. et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005; 46(1): 137-143
  30. Janiak P., Bidouard J.P., Cadrouvele C. et al. Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats. Eur. J. Pharmacol. 2006; 534: 271-279
  31. Garg J.P., Elliott W.J., Folker A. et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am. J. Hypertens. 2005; 18 (5 Pt. 1): 619 - 626
  32. Degli Esposti L., Degli Esposti E., Valpiani G. et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin. Ther. 2002; 24: 1347 - 1357
  33. Wetzels G.E., Nelemans P., Schouten J.S., Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J. Hypertens. 2004; 22: 1849 - 1855
  34. Cheung B.M., Wong Y.L., Lau C. Queen Mary Utilization of Antihypertensive Drugs Study: side-effects of antihypertensive drugs. J. Clin. Pharm. Ther. 2005; 30: 391 - 399
  35. Visser L.E., Stricker B.H., van der Velden J. et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J. Clin. Epidemiol. 1995; 48: 851 - 857
  36. Patel B.V., Remigio-Baker R.A., Mehta D. et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J. Clin. Hypertens. (Greenwich) 2007; 9(9): 692-700
  37. Patel B.V, Remigio-Baker R.A, Thiebaud P. et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. B.M.C. Fam. Pract. 2008; 9: 61

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies